Indicate\ue000 by\ue000 check\ue000 mark\ue000 if\ue000 the\ue000 registrant\ue000 is\ue000 a\ue000 well-known\ue000 seasoned\ue000 issuer,\ue000 as\ue000 defined\ue000 in\ue000 Rule\ue000 405\ue000 of\ue000 the\ue000 Securities\ue000 Act.\ue000\ue000\ue000\ue000 Yes\ue000 \ue000x\ue000\ue000\ue000\ue000 No\ue000 \ue000\u00ae Indicate\ue000 by\ue000 check\ue000 mark\ue000 if\ue000 the\ue000 registrant\ue000 is\ue000 not\ue000 required\ue000 to\ue000 file\ue000 reports\ue000 pursuant\ue000 to\ue000 Section\ue000 13\ue000 or\ue000 Section\ue000 15(d)\ue000 of\ue000 the\ue000 Act.\ue000\ue000\ue000\ue000 Yes\ue000 \ue000\u00ae\ue000\ue000\ue000\ue000 No\ue000 \ue000x Indicate\ue000 by\ue000 check\ue000 mark\ue000 whether\ue000 the\ue000 registrant\ue000 (1)\ue000 has\ue000 filed\ue000 all\ue000 reports\ue000 required\ue000 to\ue000 be\ue000 filed\ue000 by\ue000 Section\ue000 13\ue000 or\ue000 15(d)\ue000 of\ue000 the\ue000 Securities\ue000 Exchange

Indicate\ue000 by\ue000 check\ue000 mark\ue000 if\ue000 disclosure\ue000 of\ue000 delinquent\ue000 filers\ue000 pursuant\ue000 to\ue000 Item\ue000 405\ue000 of\ue000 Regulation\ue000 S-K\ue000 is\ue000 not\ue000 contained\ue000 herein,\ue000 and\ue000 will\ue000 not\ue000 be contained,\ue000 to\ue000 the\ue000 best\ue000 of\ue000 the\ue000 registrant\u2019s\ue000 knowledge,\ue000 in\ue000 definitive\ue000 proxy\ue000 or\ue000 information\ue000 statements\ue000 incorporated\ue000 by\ue000 reference\ue000 in\ue000 Part\ue000 III\ue000 of\ue000 this Form\ue000 10-K\ue000 or\ue000 any\ue000 amendment\ue000 to\ue000 this\ue000 Form\ue000 10-K.\ue000\ue000\ue000\ue000\u00ae

The\ue000 aggregate\ue000 market\ue000 value\ue000 of\ue000 the\ue000 1,978,967,503\ue000 shares\ue000 of\ue000 voting\ue000 common\ue000 equity\ue000 held\ue000 by\ue000 non-affiliates\ue000 of\ue000 the\ue000 registrant,\ue000 computed\ue000 by reference\ue000 to\ue000 the\ue000 closing\ue000 price\ue000 as\ue000 reported\ue000 on\ue000 the\ue000 New\ue000 York\ue000 Stock\ue000 Exchange,\ue000 as\ue000 of\ue000 the\ue000 last\ue000 business\ue000 day\ue000 of\ue000 the\ue000 registrant\u2019s\ue000 most\ue000 recently completed\ue000 second\ue000 fiscal\ue000 quarter\ue000 (June\ue000 30,\ue000 2008)\ue000 was\ue000 approximately\ue000 $40,628,202,837.\ue000 Bristol-Myers\ue000 Squibb\ue000 has\ue000 no\ue000 non-voting\ue000 common\ue000 equity. At\ue000 February\ue000 6,\ue000 2009,\ue000 there\ue000 were\ue000 1,979,509,306\ue000 shares\ue000 of\ue000 common\ue000 stock\ue000 outstanding.

Bristol-Myers\ue000 Squibb\ue000 Company\ue000 (which\ue000 may\ue000 be\ue000 referred\ue000 to\ue000 as\ue000 Bristol-Myers\ue000 Squibb,\ue000 BMS\ue000 or\ue000 the\ue000 Company)\ue000 was\ue000 incorporated\ue000 under\ue000 the\ue000 laws\ue000 of the\ue000 State\ue000 of\ue000 Delaware\ue000 in\ue000 August\ue000 1933\ue000 under\ue000 the\ue000 name\ue000 Bristol-Myers\ue000 Company,\ue000 as\ue000 successor\ue000 to\ue000 a\ue000 New\ue000 York\ue000 business\ue000 started\ue000 in\ue000 1887.\ue000 In\ue000 1989, Bristol-Myers\ue000 Company\ue000 changed\ue000 its\ue000 name\ue000 to\ue000 Bristol-Myers\ue000 Squibb\ue000 Company\ue000 as\ue000 a\ue000 result\ue000 of\ue000 a\ue000 merger.\ue000 The\ue000 Company,\ue000 through\ue000 its\ue000 divisions\ue000 and subsidiaries,\ue000 is\ue000 engaged\ue000 in\ue000 the\ue000 discovery,\ue000 development,\ue000 licensing,\ue000 manufacturing,\ue000 marketing,\ue000 distribution\ue000 and\ue000 sale\ue000 of\ue000 pharmaceutical\ue000 and nutritional\ue000 products.

In\ue000 January\ue000 2008,\ue000 the\ue000 Company\ue000 completed\ue000 the\ue000 divestiture\ue000 of\ue000 Bristol-Myers\ue000 Squibb\ue000 Medical\ue000 Imaging\ue000 (Medical\ue000 Imaging)\ue000 to\ue000 Avista\ue000 Capital Partners\ue000 L.P.\ue000 (Avista)\ue000 for\ue000 a\ue000 gross\ue000 purchase\ue000 price\ue000 of\ue000 approximately\ue000 $525\ue000 million,\ue000 excluding\ue000 post-closing\ue000 adjustments.\ue000 As\ue000 a\ue000 result\ue000 of\ue000 the transaction\ue000 the\ue000 Company\ue000 recorded\ue000 a\ue000 pre-tax\ue000 gain\ue000 of\ue000 $25\ue000 million\ue000 and\ue000 an\ue000 after-tax\ue000 loss\ue000 of\ue000 $43\ue000 million,\ue000 which\ue000 are\ue000 included\ue000 in\ue000 discontinued operations\ue000 in\ue000 the\ue000 consolidated\ue000 statements\ue000 of\ue000 earnings.

In\ue000 June\ue000 2008,\ue000 the\ue000 Company\ue000 acquired\ue000 Kosan\ue000 Biosciences,\ue000 Inc.,\ue000 a\ue000 developer\ue000 of\ue000 novel\ue000 oncology\ue000 products,\ue000 for\ue000 a\ue000 net\ue000 purchase\ue000 price\ue000 of approximately\ue000 $191\ue000 million.\ue000 In\ue000 connection\ue000 with\ue000 the\ue000 transaction,\ue000 the\ue000 Company\ue000 recorded\ue000 approximately\ue000 $32\ue000 million\ue000 in\ue000 acquisition-related\ue000 in- process\ue000 research\ue000 and\ue000 development\ue000 charges.

In\ue000 August\ue000 2008,\ue000 the\ue000 Company\ue000 completed\ue000 the\ue000 divestiture\ue000 of\ue000 its\ue000 ConvaTec\ue000 business\ue000 to\ue000 Cidron\ue000 Healthcare\ue000 Limited,\ue000 an\ue000 affiliate\ue000 of\ue000 Nordic\ue000 Capital Fund\ue000 VII\ue000 and\ue000 Avista,\ue000 for\ue000 $4.1\ue000 billion.\ue000 As\ue000 a\ue000 result\ue000 of\ue000 the\ue000 transaction,\ue000 the\ue000 Company\ue000 recorded\ue000 a\ue000 pre-tax\ue000 gain\ue000 of\ue000 $3.4\ue000 billion,\ue000 $2.0\ue000 billion\ue000 net\ue000 of\ue000 tax, subject\ue000 to\ue000 certain\ue000 post-closing\ue000 adjustments,\ue000 which\ue000 are\ue000 included\ue000 in\ue000 discontinued\ue000 operations\ue000 in\ue000 the\ue000 consolidated\ue000 statements\ue000 of\ue000 earnings.

The\ue000 Company\ue000 reports\ue000 financial\ue000 and\ue000 operating\ue000 information\ue000 in\ue000 two\ue000 segments\u2014Pharmaceuticals\ue000 and\ue000 Nutritionals.\ue000 The\ue000 Nutritionals\ue000 segment\ue000 is operated\ue000 through\ue000 the\ue000 Company\u2019s\ue000 subsidiary\ue000 Mead\ue000 Johnson\ue000 Nutrition\ue000 Company\ue000 (Mead\ue000 Johnson).\ue000 In\ue000 August\ue000 2008,\ue000 the\ue000 Company\ue000 completed\ue000 the divestiture\ue000 of\ue000 its\ue000 ConvaTec\ue000 business\ue000 to\ue000 Cidron\ue000 Healthcare\ue000 Limited\ue000 and\ue000 Avista.\ue000 The\ue000 results\ue000 of\ue000 the\ue000 ConvaTec\ue000 business,\ue000 previously\ue000 presented\ue000 as the\ue000 former\ue000 ConvaTec\ue000 operating\ue000 segment,\ue000 are\ue000 included\ue000 in\ue000 discontinued\ue000 operations\ue000 in\ue000 all\ue000 periods\ue000 presented.\ue000 In\ue000 January\ue000 2008,\ue000 the\ue000 Company completed\ue000 the\ue000 divestiture\ue000 of\ue000 its\ue000 Medical\ue000 Imaging\ue000 business\ue000 to\ue000 Avista,\ue000 the\ue000 results\ue000 of\ue000 which\ue000 are\ue000 included\ue000 in\ue000 discontinued\ue000 operations\ue000 in\ue000 all\ue000 periods presented.

The\ue000 Pharmaceuticals\ue000 segment\ue000 competes\ue000 with\ue000 other\ue000 worldwide\ue000 research-based\ue000 drug\ue000 companies,\ue000 smaller\ue000 research\ue000 companies\ue000 and\ue000 generic\ue000 drug manufacturers.\ue000 These\ue000 products\ue000 are\ue000 sold\ue000 worldwide,\ue000 primarily\ue000 to\ue000 wholesalers,\ue000 retail\ue000 pharmacies,\ue000 hospitals,\ue000 government\ue000 entities\ue000 and\ue000 the\ue000 medical profession.\ue000 The\ue000 Company\ue000 manufactures\ue000 these\ue000 products\ue000 in\ue000 the\ue000 U.S.\ue000 and\ue000 Puerto\ue000 Rico\ue000 and\ue000 in\ue000 11\ue000 foreign\ue000 countries.

U.S.\ue000 pharmaceutical\ue000 net\ue000 sales\ue000 accounted\ue000 for\ue000 60%,\ue000 58%\ue000 and\ue000 54%\ue000 of\ue000 total\ue000 pharmaceutical\ue000 net\ue000 sales\ue000 in\ue000 2008,\ue000 2007\ue000 and\ue000 2006,\ue000 respectively,\ue000 while pharmaceutical\ue000 net\ue000 sales\ue000 in\ue000 Europe,\ue000 Middle\ue000 East\ue000 and\ue000 Africa\ue000 accounted\ue000 for\ue000 24%,\ue000 25%\ue000 and\ue000 28%\ue000 of\ue000 total\ue000 pharmaceutical\ue000 net\ue000 sales\ue000 in\ue000 2008,\ue000 2007 and\ue000 2006,\ue000 respectively.\ue000 Pharmaceutical\ue000 net\ue000 sales\ue000 in\ue000 Japan\ue000 accounted\ue000 for\ue000 3%\ue000 of\ue000 total\ue000 pharmaceutical\ue000 net\ue000 sales\ue000 in\ue000 2008\ue000 and\ue000 4%\ue000 in\ue000 each\ue000 of\ue000 2007 and\ue000 2006.